BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

British Journal of Radiology (1990) 63, 468-475
© 1990 British Institute of Radiology
doi: 10.1259/0007-1285-63-750-468

This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Floersheim, G. L.
Right arrow Articles by Bieri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Floersheim, G. L.
Right arrow Articles by Bieri, A.

Further studies on selective radioprotection by organic zinc salts and synergism of zinc aspartate with WR 2721

G. L. Floersheim, MD and A. Bieri

Laboratory for Transplantation Biology, Department of Research, Zentrum für Lehre und Forschung, Kantonsspital, Hebelstrasse 20, 4031, Basel, Switzerland

The organic zinc salts zinc aspartate, zinc histidine, zinc orotate and zinc acetate reduced the fall of the haematocrit, thrombocytes, erythrocytes and leucocytes in irradiated mice. In general, zinc aspartate was more effective than the other organic zinc salts. Protection of the haematocrit and thrombocytes by small doses of the aminothiol radioprotector WR2721 was markedly improved by the concomitant administration of small doses of zinc aspartate. Zinc aspartate was the only one of the four tested organic zinc salts that did not inhibit in any instance the regression induced by radiotherapy of human tumours grown as xenografts in immunosuppressed mice. This also applied to the combination of zinc aspartate with WR2721. In an experiment performed to determine the toxicity of the combined regimen, a dose of zinc aspartate which afforded synergistic haematological protection did not enhance the toxicity of WR2721. The synergism of zinc aspartate with WR2721 and the differential radioprotection of the combined protocol may make it possible in clinical cancer radiotherapy to obtain selective radioprotection at a lower toxicity giving an improved therapeutic ratio compared with WR2721 alone.

Received for publication November 1, 1988.


This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Samuni, D. Coffin, A. M. DeLuca, W. G. DeGraff, D. J. Venson, I. Ambudkar, M. Chevion, and J. B. Mitchell
The Use of Zn-Desferrioxamine for Radioprotection in Mice, Tissue Culture, and Isolated DNA
Cancer Res., January 1, 1999; 59(2): 405 - 409.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 1990 by the British Institute of Radiology.